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Abstract
Introduction
The pathophysiology of preeclampsia is largely unknown. Serum placental induced growth
factor (PlGF) levels are decreased during second trimester pregnancy. Aberrant DNA meth-
ylation is suggested to be involved in the etiology of preeclampsia (PE). We hypothesize
that DNA methylation is altered in PE placentas determined the methylation index by mea-
suring placental S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) levels.
In addition, we assessed global DNA methylation status by long-interspersed nuclear ele-
ment-1 (LINE-1) and DNA methylation status of the PlGF gene.
Methods
Placental tissue of 11 early onset PE (EOPE), 11 late onset PE (LOPE) and 60 controls con-
sisting of 25 uncomplicated controls 20 fetal growth restriction (FGR) and 15 preterm births
(PTB) controls was collected from a nested case-control study of The Rotterdam Pericon-
ceptional Cohort. RNA and DNA was isolated from placental tissue and DNA was treated
with sodium bisulfite. SAM and SAH levels were measured by LC-ESI-MS/MS. Methylation
of LINE-1 and PlGF genes was analyzed by Sequenom Epityper and. mRNA expression of
PlGF was assessed with qPCR. Differences were assessed by analysis of covariance
(ANCOVA) corrected for gestational age and birth weight.
Results
Placental SAM levels were significantly lower in placental tissue of EOPE pregnancies com-
pared to PTB controls (mean difference -240 ± 71.4 nmol/g protein, P = 0.01). PlGF DNA
methylation was decreased in placental tissue of EOPE cases versus LOPE (mean differ-
ence -17.4 ± 5.1%, P = 0.01), uncomplicated controls (mean difference -23.4 ± 5.4%%,
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P <0.001), FGR controls (mean difference -17.9 ± 4.6%, P = 0.002) and PTB controls (mean
difference -11.3 ± 3.8% P = 0.04). No significant differences were observed in SAH, SAM:
SAH ratio, LINE-1 DNA methylation and PlGF mRNA expression between groups.
Discussion
The hypomethylation state of the placenta in EOPE, which is reflected by lower SAM and
PlGF DNA hypomethylation underlines the possible role of placental DNA hypomethylation
in the pathophysiology of EOPE, which needs further investigation.
Introduction
Preeclampsia (PE) is one of the most severe maternal pregnancy complications worldwide and
affects 2–8% of all pregnancies [1]. The pathophysiological mechanism is not fully understood
and therapy is mostly aimed at reducing blood pressure rather than to cure the disease. The
molecular mechanism is thought to involve defective invasion of the spiral arteries into the
maternal blood stream, which leads to maternal endothelial dysfunction and concomitant
high blood pressure [1, 2]. However, preeclampsia is a heterogeneous disorder: it can occur as
early-onset (EOPE;�34 weeks of gestation) or late-onset (LOPE; >34 weeks of gestation) dis-
ease. Both phenotypes share common risk factors but differences also exists: EOPE is associ-
ated with more adverse (fetal) effects compared to LOPE [3].
Previously, we and others demonstrated a role of one-carbon metabolism in relation to PE
[1, 4–7]. This metabolism donates methyl groups for cellular methylation reactions. S-adeno-
sylmethionine (SAM) donates its methyl group to DNA after which S-adenosylhomocysteine
(SAH) is formed. SAH can be hydrolyzed into homocysteine by SAH hydrolase by a reversible
reaction. SAH is suggested to be a potent inhibitor of methylation reactions [8]. Elevated levels
of plasma homocysteine, which is a sensitive marker of disturbed 1-carbon metabolism, has
been shown to be associated with increased levels of SAH, decreased methylation index (SAM:
SAH ratio) and decreased global DNA methylation (such as methylation of LINE-1 repetitive
elements) and decreased methylation of imprinted genes [8–10]. Several studies demonstrated
an imbalance in the release of soluble fms-like tyrosine kinase (sFlt-1) and placental growth
factor (PIGF) into the maternal blood stream in preeclamptic women [11–13]. The presence of
sFlt-1 competes with Flt-1 in the binding of PlGF and causes maternal endothelial dysfunction
resulting in preeclampsia. During second trimester pregnancy elevated levels of sFLt-1 and
decreased levels of PIGF have been observed in preeclamptic complicated pregnancies com-
pared to normotensive pregnancies [11, 14, 15] resulting in an increased sFlt-1/PlGF ratio.
We hypothesized that DNA methylation is decreased in placental tissue of PE pregnancies
and assessed SAM and SAH levels, global LINE-1 DNA methylation and methylation of the
PlGF gene in placental tissue of EOPE and LOPE pregnancies compared to uncomplicated
controls, fetal growth restricted (FGR) controls and preterm birth (PTB) controls.
Methods
Placental material
Between June 2011 and June 2013 placental tissue was collected from selected patients for a
nested case-control study of the Rotterdam Periconceptional Cohort (Predict study), an ongo-
ing prospective tertiary hospital-based cohort study conducted at the Erasmus MC University
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Medical Center Rotterdam [16]. EOPE and LOPE cases were selected as cases and uncompli-
cated pregnancies were selected as controls. In addition, we oversampled the uncomplicated
control group with placental tissue from fetal growth restricted (FGR) pregnancies and pre-
term births (PTB) as additional controls to reduce confounding by differences in gestational
age and birth weight as described previously [17].
PE was defined according to the International Society for the Study of Hypertension in
Pregnancy as gestational hypertension of at least 140/90 mmHg accompanied by an urine pro-
tein/creatinine ratio of� 30 mg/mmol, arising de novo after the 20th week of gestation. EOPE
and LOPE were defined as being PE diagnosed before and after 34 weeks of gestation, respec-
tively [18]. Uncomplicated control pregnancies were defined as pregnancies without PE, gesta-
tional hypertension, FGR or PTB. FGR controls were selected based upon fetal weight below
the 10th percentile for gestational age. Birthweight percentiles were calculated according to the
reference curves of the Dutch Perinatal Registry [19]. PTB controls were selected as spontane-
ous delivery between 22 and 37 weeks of gestation. Woman with multiple birth pregnancies or
pregnancies complicated by fetal congenital malformations were excluded from this study. All
women signed a written informed consent and the study protocol was approved by the medical
ethical committee of the ErasmusMC (METC number 2004–227).
Sample collection
Within 30 minutes after delivery of the placenta, samples of 0.5 cm3 were taken from the fetal
side of the placental tissue at 4 different sites in a 3 cm radius around the umbilical cord inser-
tion, after carefully removing the membranes and 2 mm of the top placental layer. Placental
tissue from 4 different biopsies was quickly rinsed in PBS and was snap frozen in liquid nitro-
gen in Eppendorf tubes and was stored at -80˚ until further analysis. Placental tissue was
grinded from 30 mg tissue of one placental biopsy and frozen placental powder was directly
added to a cell lysis buffer and stored in Eppendorf tubes at -80 ˚C until further analysis. Sub-
sequently, genomic DNA and RNA was extracted using the Allprep DNA/RNA isolation mini
kit (Qiagen, Hilden, Germany), according to manufacturer’s instructions. Another aliquot of
grinded placental tissue was mixed in an acidic saline solution (800μl saline, 80μl 1M Acetic
Acid) for SAM, SAH and total protein measurement.
Placental SAM and SAH measurements
S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) concentrations were deter-
mined in grinded placental tissue with an isotope dilution liquid chromatography tandem MS
method (ID-LC-MS/MS) as adapted from Gellekink et al [20]. In short, the acidified placental
extracts were neutralized with 1 M NH3 and subjected to a SPE sample clean-up. 10 μl of sam-
ple was then injected on a 50x2.1 mm HPLC Atlantis C18 column (Waters, Etten-Leur, the
Netherlands) and eluted using a methanol gradient in 0.1% aqueous acetic acid. Detection was
performed on a Quattro Premier XE mass spectrometer (Waters, Etten-Leur, the Nether-
lands). The concentration of total protein in the grinded placental extracts was determined on
a Cobas 701 analyzer using the urine/CSF total protein test kit (Roche Diagnostics, Almere,
the Netherlands). The amount of SAM and SAH was expressed as nmol/g protein.
Quantification of LINE-1 and PlGF DNA methylation
Global DNA methylation was measured by LINE-1 repetitive elements (Genbank: X58075) as
previously described by Wang et al [21]. Primers of PlGF gene were designed according to
Genbank sequences NC_000014.9. The following primers were selected: L1-FOR: 5’-aggaa
gagagGTGTGAGGTGTTAGTGTGTTTTGTT -3’, L1-REV 5’ -cagtaatacgactcacta
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tagggagaaggctATATCCCACACCTAACTCAAAAAAT -3’, PlGF-FOR 5’-aggaagaga
gGTTGGATTTTTGGATGTTTTTATTT -3’, and PlGF-REV 5’-cagtaatacgactcacta
tagggagaaggctCAAACAACAACTCCCTTCTAAAACT -3’,. DNA (500ng) was bisulfite
treated with EZ DNA methylation kit (Zymo research, USA) according to the instructions of
the manufacturer. Bisulfite treated DNA was dissolved in a Tris/0.1xEDTA buffer in a final
concentration between 5 and 7 ng/μL. All bisulfite treated DNA samples were stored at -80˚C.
PCR was performed in quadruplicate within 30 days after bisulfite treatment and all PCR reac-
tions were performed simultaneously. Methylated DNA and unmethylated DNA control
(Zymo research, USA) were mixed in a 4:1 ratio as a positive control. In addition, genomic
DNA isolated from blood leucocytes was used throughout the whole procedure as a positive
control. Bisulfite treatment was performed for 20 samples each run and contained both the
Zymo control as well as the blood sample control besides 18 placental samples. PCR was per-
formed in a total volume of 12μl. Reaction mixture contained buffer 1x, dNTP (0.2mM),
MgCl2 (1.5mM), forward/reverse primer (4 pmol), Amplitaq Gold (0.5 units, Life Technolo-
gies, Netherlands) and 2μl bisulfite treated DNA. PCR program followed a touch down proce-
dure with an initial denaturation at 95˚ for 10 min. First 5 cycles of denaturation at 95˚ for 20
sec, annealing at 65˚ for 30 sec, elongation at 72˚ for 1 min. Second 5 cycles of denaturation at
95˚ for 20 sec, annealing at 58˚ for 30 sec, elongation at 72˚ for 1 min. Followed by 39 cycles of
denaturation at 95˚ for 20 sec, annealing at 53˚ for 30 sec, elongation at 72˚ for 1 min and a
final elongation at 72˚ for 3 min. 3μl of the PCR product was tested on gel. All PCR products
were stored at -20˚C until Sequenom analysis. Sequenom analysis (triplicate) was performed
accordingly to the instructions of the manufacturer. All samples for LINE-1 measurement
were analyzed on a single spectrochip, the same was done for PlGF measurement. Methylation
percentage was calculated by MassARRAY Epityper Analyzer Software (Sequenom, USA).
Validation of LINE-1 and PlGF methylation assays
LINE_1 amplicon detected 8 CpG sites of which CpG site 4 was omitted because of a silent sig-
nal and CpG_10 could not be measured because of low mass error. Mean percentage of meth-
ylation, standard deviation (SD), and coefficient of variation (CV) were calculated from
triplicate measurements of each CpG site. CV had to be less than 10% to be able to measure
LINE-1 DNA methylation precisely. The PlGF amplicon consisted of 15 CpG sites of which 6
CpG sites were omitted due to low/high mass or silent signal. Of the 9 CpG sites that poten-
tially could be quantified only CpG site 1 could be quantified, which is located in the 5’flanking
region of the PlGF gene. Other 8 CpG sites had a methylation of less than 5%, which resulted
in a CV>20%. Mean percentage of methylation, SD, and CV were calculated from triplicate
measurements of each CpG site. Mean methylation of PLGF was lower than LINE-1 methyla-
tion and for this reason we could not measure PLGF methylation with the same precision as
LINE-1. We therefore used CV<20% as cut-off instead of CV<10%.
PlGF mRNA quantification
RNA was isolated from 82 placental samples of PE-complicated pregnancies and controls from
the same biopt as from which DNA was isolated and RNA quality was assessed with the 2100
Bioanalyzer and RNA 6000 Nano kit (Agilent Technologies, Germany). Of these samples, 8
recorded a RIN number<2 and were left out for further procedure. Of the remaining 74 sam-
ples two recorded a RIN = 7, all other samples showed a RIN>8 500 ng of RNA was used for a
single RT reaction using the Iscript RT supermix kit (Bio-Rad, The Netherlands) in a total vol-
ume of 20 μL (both Oligo-dT and random priming). Incubation was done for 5 min at 25˚C,
20 min at 46 ˚C and 1 min at 95˚C. RT reactions were performed in series of 22 samples
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combined with one No-RT control reaction. Afterwards RT reaction samples were diluted 2.5
times with sterile water. Expression analysis was performed in a 96-well format on a Taqman
7500 fast analyzer (ThermoFisher Scientific, USA). The following taqman tests were used; PlGF
(Hs00182176_m1); Eukaryotic 18S rRNA (Hs99999901_s1) and Beta actin (H99999903_m1).
Taqman tests were performed with 2 μL cDNA, 10 μL Taqman fast advanced mastermix and
1 μL expression assay mix in a total volume of 20 μL. Fast Cycling was done for 2 min 50˚C., 2
min 95˚C and 40 cycles of 3 sec 95˚C, 30 sec 60˚C. As 18S RNA was highly expressed in placen-
tal tissue taqman cycling was reduced to 30 cycles. Samples were run in duplicate and were
repeated if Ct difference between the duplicates was found to be>0.3 Ct value. Data was
analyzed with Qbase+ (Biogazelle, Belgium). Of all cDNA samples a pooled control sample
was made. This pooled sample was used for a 10-times dilution series on every plate. These
dilution series were used for PCR efficiency correction. Efficiencies found for PlGF, 18S and
ACTB were 1.95, 1.95 and 1.91 respectively. Normalization was done with 18S and ACTB
(M = 0.562). CNRQ values are calculated relatively to study average and were exported and
used for further statistical analysis.
Statistical analysis
Normality of the tested variables was checked manually by histrograms and was in addition
analyzed by Shapiro-Wilk test. Means with SD were calculated from normal distributed vari-
ables and median with interquartile range (IQR) were presented for skewed variables. Differ-
ences in maternal and neonatal characteristics between the five groups were assessed using
ANOVA for normal distributed variables and Kruskal-Wallis test for skewed variables. Differ-
ences in mode of delivery, fetal gender and birth weight percentage were calculated with Chi-
square test.
Difference in methylation markers among the groups were assessed by analysis of variance
(ANOVA). In addition, correction for differences in gestational age and birth weight were
assessed by univariate analysis of covariance (ANCOVA) followed by Bonferoni post-hoc
analysis. LINE-1 amplicon was analyzed as the mean of all CpGs per sample to assess methyl-
ation of the whole differentially methylated region (DMR). PlGF DNA methylation was
skewed but analysis showed that transformation did not result in normality. However, as the
Shapiro-Wilk test statistic of the log-transformed PlGF DNA methylation improved after
log-transformation (0.942 versus 0.836, log_PlGF versus PlGF, respectively)) we used log-
transformed PlGF DNA methylation in further analysis. P<0.05 was considered to be signifi-
cantly. Bonferroni correction was applied to correct for multiple comparisons of independent
methylation markers. We accounted for five independent multiple comparisons (SAM, SAH,
SAM:SAH ratio, LINE-1 methylation and PlGF methylation). P<0.01 was considered statisti-
cally significant after Bonferroni correction (i.e. P = 0.05/5). Correlation between methyla-
tion markers was assessed with Pearson correlation. All analysis were performed in IBM
SPSS statistics 25.
Results
Baseline descriptives
Descriptives of the cohort are described in Table 1. Systolic- and diastolic blood pressure were
significantly increased in women with EOPE and LOPE complicated pregnancies (Table 1).
In addition, significant differences in birth weight and gestational age were present among
EOPE, LOPE and the control groups (Table 1, ANOVA P<0.001).
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Placental SAM and SAH levels
SAM levels were significantly different among the five groups (crude P = 0.002, Table 2). Post
hoc analysis demonstrated significantly lower SAM levels in placental tissue from EOPE com-
plicated pregnancies compared to PTB controls, which was independent from differences in
gestational age and birthweight (mean difference -240 ± 71.4 nmol/g protein, P = 0.01,
Table 2). However, this difference attenuated after Bonferoni correction as it did not reach the
predefined Bonferoni significance level of P<0.01. SAH levels were not significantly different
between EOPE, LOPE and each of the control groups (Table 2). SAM:SAH ratio was slightly
lower in EOPE compared to PTB controls, but this was not statistically significant (mean dif-
ference -2.5 ± 0.99, P = 0.13). No differences were observed in SAM:SAH ratio between LOPE
and each of the control groups (Table 2).
Table 1. Maternal and neonatal characteristics.
EOPE LOPE Uncomplicated controls Normotensive FGR controls Normotensive PTB controls P value
N = 11 N = 11 N = 25 N = 20 N = 15
Maternal
Age (y) 31.2 ± 4.0 33.6 ± 4.7 31.8 ± 5.3 29.6 ± 6.3 31.4 ± 3.3 0.30
SBD (mm Hg) 174 ± 19 150 ± 10 129 ± 12 130 ± 14 126 ± 17 <0.001
DBD (mm Hg) 99 ± 16 94 ± 11 76 ± 6 75 ± 9 79 ± 14 <0.001
Delivery (% vaginal) 1 (9%) 6 (55%) 18 (72%) 12 (60%) 12 (80%) 0.01
Neonatal
Sex (male), N (%) 3 (27) 5 (45) 14 (56) 12 (60) 7 (47) 0.464
Gestational age (days) 215 (24) 265 (16) 279 (13) 267 (15) 244 (62) <0.001
Birthweight (grams) 1181 ± 356 3363 ± 662 3788 ± 398 2451 ± 362 2259 ± 958 <0.001
Birth weight <10th, N (%) 11 (100) 1 (9) 0 (0) 20 (100) 0 (0) <0.001
Data are presented as mean ± standard deviation or as ^median (IQR) for skewed variables for continuous variables and as number and percentage for dichotomous
variables. EOPE = early onset PE; LOPE = late onset PE; FGR = fetal growth retardation; PTB = preterm birth; SBD = systolic blood pressure; DBD = diastolic blood
pressure.
https://doi.org/10.1371/journal.pone.0226969.t001
Table 2. Biomarkers in placental tissue of PE complicated pregnancies and controls.
EOPE LOPE Controls FGR controls PTB controls Crude P Adjusted P
SAM (nmol/g protein),(n) 397 ± 109� (10) 345 ± 119 (10) 384 ± 147 (25) 360 ± 128 (20) 568 ± 241 (14) 0.002 0.02
SAH (nmol/g protein) (n) 95.8 ± 27.0 (10) 79.7 ± 29.0 (10) 78.5 ± 28.4 (25) 76.5 ± 31.8 (20) 84.1 ± 27.1 (14) 0.049 0.75
SAM:SAH ratio,(n) 4.4 ± 1.4 (10) 4.9 ± 2.4 (10) 5.3 ± 2.0 (25) 5.1 ± 2.3 (20) 6.8 ± 2.1 (14) 0.07 0.07
LINE-1 DMR methylation (%), (n) 22.1 ± 2.4 (11) 22.7 ± 1.9 (11) 22.8 ± 2.1 (25) 22.0 ± 2.5 (20) 22.3 ± 2.9 (14) 0.77 0.15
PlGF methylation (%)$, (n) 13.3 [3.7]# (11) 13.0 [2.3] (11) 14.0 [2.8] (25) 12.2 [4.6] (20) 15.2 [7.6] (14) 0.15 0.001
PlGF mRNA^, (n) 1.19 ± 0.80 (10) 1.26 ± 0.69 (10) 1.21 ± 0.42 (21) 0.93 ± 0.54 (18) 1.22 ± 0.55 (14) 0.49 0.61
Data are presented as mean ± standard deviation or as $median (IQR) for skewed variables. Crude P value of ANOVA test between 5 groups; Adjusted P value of
ANCOVA corrected for gestational age and birthweight between 5 groups.
�P = 0.01 compared to PTB controls.
#P<0.05 compared to either LOPE, uncomplicated controls, FGR controls and PTB controls. EOPE = early onset PE; LOPE = late onset PE; FGR = fetal growth
retardation; PTB = preterm birth; SAM = S-adenosylmethionine; SAH = S-adenosylhomocysteine; LINE-1 = long-interspersed nuclear element 1; PlGF = Placental
growth factor.
^Calibrated normalized relative quantity as calculated with Qbase+
https://doi.org/10.1371/journal.pone.0226969.t002
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Placental LINE-1 and PlGF DNA methylation
LINE-1 DNA methylation was not significantly different in placental tissue among the groups
(mean difference ranged from -0.009 till -0.02, P>0.05, Table 2). Placental PlGF DNA methyla-
tion was not significant among groups (mean difference ranged from -0.07 till 0.01, crude
P = 0.15, Table 2). However, after correction for gestational age and birthweight PlGF DNA
methylation was lower in EOPE compared to LOPE (mean difference -17.4 ± 5.1%, P = 0.01),
uncomplicated controls (mean difference -23.4 ± 5.4%, P< 0.001), FGR controls (mean differ-
ence -17.9 ± 4.6%, P = 0.002) and PTB controls (mean difference -11.3 ± 3.8%, P = 0.04). The
difference between EOPE compared to uncomplicated controls and FGR controls met the pre-
defined Bonferoni level of P<0.01. Placental PlGF DNA methylation was not significantly
lower in LOPE placentas compared to each of the control groups (Table 2).
Placental PlGF mRNA levels
PlGF mRNA levels were not significantly different between EOPE, LOPE and each of the con-
trol groups (mean difference ranged from -0.01 till 0.43 after correction for gestational age and
birth weight, P>0.05, Table 2). In addition, PlGF mRNA levels were modestly negatively corre-
lated to PlGF DNA methylation in uncomplicated controls (R = -0.51, P = 0.02), whereas in
EOPE, LOPE, FGR controls and PTB controls no significant correlation was present.
Correlation of methylation markers
We investigated correlation of PlGF DNA methylation and SAM with other biomarkers. SAM
was significantly correlated to SAH (r = 0.45, P = 0.001), SAM:SAH ratio (r = 0.51, P < 0.001),
birth weight (r = -0.26, P = 0.02), and gestational age (r = -0.39, P = 0.006). In addition, PlGF
DNA methylation was significantly correlated to SAM levels (R = 0.31, P = 0.006), SAM:SAH
ratio (R = 0.24, P = 0.04), LINE-1 DNA methylation (R = 0.40, P<0.001) and gestational age
(R = -0.35, P = 0.02) although correlation coefficients were modest (R<0.80).
Discussion
The pathophysiological mechanism of PE is unknown and studies have suggested a role of epi-
genetics. We show significantly lower SAM levels in placental tissues from EOPE complicated
pregnancies compared to PTB controls. Concomitantly, PlGF DNA methylation levels were
decreased in EOPE pregnancies compared to LOPE and each of the control groups. No signifi-
cant differences were found in LOPE and neither was global LINE-1 DNA methylation and
PlGF mRNA expression significant different between EOPE, LOPE and each of the control
groups.
Few studies have investigated DNA methylation at a global level and several studies focused
at candidate genes [22], [23]. We and others provided evidence for a role of some novel epige-
netic loci using methylation arrays although these results need to be validated in larger cohorts
[24, 25]. None of the candidate studies have identified PlGF as target locus in PE neither was
the PlGF locus identified in genome-wide methylation studies [26–29]. However, most studies
consisted of only a few patients or did not correct for differences in confounders such as gesta-
tional age, which could have complicated the reported findings.
Based on the previous described role of altered one-carbon metabolism in relation to PE we
hypothesized that changes in SAM, SAH and SAM:SAH ratio are present in PE, which lead to
decreased methylation. We showed significantly lower SAM levels in placental tissue of EOPE
pregnancies compared to PTB controls, which result in a lower SAM:SAH ratio, although this
ratio was not significant (P = 0.13). These lack of significant lower SAM:SAH ratio might be
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caused by the relative small sample size of our study. SAM:SAH ratio has been described as the
methylation potential of the cell and lower levels of SAM or are expected to be associated with
less methylation. In addition, we did find a modest positive correlation of placental SAM levels
with PlGF DNA methylation, which suggests that less methyl donor availability from SAM
leads to decreased PlGF DNA methylation. More studies with larger sample size are necessary
to evaluate the potential role of SAM in PE.
We were not able to demonstrate differences in placental LINE-1 methylation between PE
pregnancies and controls. Not many studies have investigated the role of global methylation
measured by LINE-1 repeats in preeclampsia. Placental LINE-1 DNA hypermethylation was
found in two studies [30, 31] whereas another study found LINE-1 hypomethylation [23, 32].
In three other studies, placental LINE-1 methylation was not significantly changed in PE com-
pared to controls [33–35], which is in agreement with our results that LINE-1 methylation in
placental tissue of PE complicated pregnancies is not different from control pregnancies. How-
ever, more studies are necessary to draw a firm conclusion.
In our study we assessed placental methylation status of PlGF in PE complicated pregnan-
cies and compared this to uncomplicated pregnancies and pregnancies complicated by FGR
and PTB. In most studies, DNA methylation of PE complicated pregnancies was compared to
uncomplicated controls. However, uncomplicated controls differ significantly from PE com-
plicated pregnancies in gestational age and birth weight. To circumvent this we included
FGR-, and PTB complicated controls, which are more comparable in birth weight and gesta-
tional age to PE complicated pregnancies. However, despite including these control groups we
still observed significant differences in birth weight and gestational age between PE compli-
cated pregnancies and PTB- and FGR complicated controls for which we corrected. In addi-
tion, we found a modest negative correlation between PlGF DNA methylation and SAM levels
with gestational age. In addition, SAM was also correlated to birth weight. These findings
demonstrate that correction for birth weight and gestational age is needed to assess indepen-
dency and also underlines that these methylation levels change during pregnancy, which war-
rant further studies during second trimester pregnancy.
We demonstrated PlGF DNA hypomethylation in placental tissue from EOPEpregnancies
compared to each of the control groups, which was not present in LOPE. The underlying
mechanism in EOPE and LOPE differs. It has been suggested that in EOPE poor placentation
plays a dominant role, whereas in LOPE inflammatory processes are involved [1]. Studies have
shown that PlGF levels are lower and have better diagnostic ability in EOPE than LOPE, which
underlines our finding of PlGF DNA hypomethylation in EOPE but not in LOPE [36, 37].
To assess whether the observed lower PlGF DNA hypomethylation in EOPE is associated
with lower PlGF mRNA expression we quantified mRNA expression in placental tissue but did
not find evidence for changes in PlGF mRNA levels between EOPE, LOPE, and each of the
control groups, which is in line with a previous study which showed that PlGF mRNA expres-
sion was not altered in EOPE placentas [38].
Interestingly, we did find that PlGF DNA methylation was negatively correlated to PlGF
mRNA expression in uncomplicated controls, whereas in pregnancies complicated by EOPE,
LOPE, FGR or PTB no significant correlation was observed. This suggests that under physio-
logical circumstances PlGF mRNA expression might be regulated by PlGF methylation. How-
ever, under pathophysiological circumstances, such as EOPE, different regulation of PlGF
methylation and mRNA expression occurs, which need to be further examined in future
studies.
During second trimester pregnancies lower PlGF plasma levels have been observed in
EOPE pregnancies. In our study PlGF DNA methylation was not associated with PlGF mRNA
expression, which could have the following explanations; 1) PlGF promoter DNA methylation
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does lead to changes in PlGF mRNA expression, 2) due to large variation in PlGF mRNA
expression we were not able to detect subtle differences in mRNA expression, 3) the physiolog-
ical mechanism of PlGF downregulation at birth might differ from second trimester preg-
nancy. Future studies investigating PlGF DNA methylation in maternal plasma or chorionic
villi obtained during second trimester pregnancy will be needed to assess whether the lower
PlGF DNA methylation levels can be used to predict EOPE in the near future.
This is the first study that assessed placental DNA methylation of global markers of methyl-
ation and PlGF DNA methyalation in preeclampsia. We showed lower SAM and PlGF DNA
hypomethylation in placental tissue of EOPE complicated pregnancies compared to PTB con-
trols. However as changes in methylation markers were modest more studies are needed to val-
idate our findings and to assess the clinical value in relation to prediction of EOPE during
first-trimester pregnancy.
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